116 related articles for article (PubMed ID: 30274060)
1. Praziquantel systems with improved dissolution rate obtained by high pressure homogenization.
Gonzalez MA; Ramírez Rigo MV; Gonzalez Vidal NL
Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():28-35. PubMed ID: 30274060
[TBL] [Abstract][Full Text] [Related]
2. Structural Elucidation of Poloxamer 237 and Poloxamer 237/Praziquantel Solid Dispersions: Impact of Poly(Vinylpyrrolidone) over Drug Recrystallization and Dissolution.
Orlandi S; Priotti J; Diogo HP; Leonardi D; Salomon CJ; Nunes TG
AAPS PharmSciTech; 2018 Apr; 19(3):1274-1286. PubMed ID: 29313262
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel.
Passerini N; Albertini B; Perissutti B; Rodriguez L
Int J Pharm; 2006 Aug; 318(1-2):92-102. PubMed ID: 16697539
[TBL] [Abstract][Full Text] [Related]
4. Unexpected solvent impact in the crystallinity of praziquantel/poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study.
Costa ED; Priotti J; Orlandi S; Leonardi D; Lamas MC; Nunes TG; Diogo HP; Salomon CJ; Ferreira MJ
Int J Pharm; 2016 Sep; 511(2):983-93. PubMed ID: 27506511
[TBL] [Abstract][Full Text] [Related]
5. Combining Mechanochemistry and Spray Congealing for New Praziquantel Pediatric Formulations in Schistosomiasis Treatment.
Albertini B; Perissutti B; Bertoni S; Zanolla D; Franceschinis E; Voinovich D; Lombardo F; Keiser J; Passerini N
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30870971
[TBL] [Abstract][Full Text] [Related]
6. Dissolution and oral bioavailability enhancement of praziquantel by solid dispersions.
Liu Y; Wang T; Ding W; Dong C; Wang X; Chen J; Li Y
Drug Deliv Transl Res; 2018 Jun; 8(3):580-590. PubMed ID: 29450806
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate.
Salazar-Rojas D; Maggio RM; Kaufman TS
Eur J Pharm Sci; 2020 Apr; 146():105267. PubMed ID: 32061654
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice.
El-Lakkany N; Seif El-Din SH; Heikal L
Eur J Drug Metab Pharmacokinet; 2012 Dec; 37(4):289-99. PubMed ID: 22460595
[TBL] [Abstract][Full Text] [Related]
9. Orphan Formulations in Pediatric Schistosomiasis Treatment: Development and Characterization of Praziquantel Nanoparticle-Loaded Powders for Reconstitution.
Gonzalez MA; Ramírez Rigo MV; Gonzalez Vidal NL
AAPS PharmSciTech; 2019 Oct; 20(8):318. PubMed ID: 31620905
[TBL] [Abstract][Full Text] [Related]
10. Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel.
Münster M; Schoch C; Schmidt C; Breitkreutz J
Eur J Pharm Sci; 2017 Nov; 109():446-454. PubMed ID: 28887230
[TBL] [Abstract][Full Text] [Related]
11. Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children.
Trastullo R; Dolci LS; Passerini N; Albertini B
Int J Pharm; 2015 Nov; 495(1):536-550. PubMed ID: 26386139
[TBL] [Abstract][Full Text] [Related]
12. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
13. Dissolution properties of praziquantel--PVP systems.
el-Arini SK; Leuenberger H
Pharm Acta Helv; 1998 Jul; 73(2):89-94. PubMed ID: 9700937
[TBL] [Abstract][Full Text] [Related]
14. Nanoconfinement of a Pharmaceutical Cocrystal with Praziquantel in Mesoporous Silica: The Influence of the Solid Form on Dissolution Enhancement.
Salas-Zúñiga R; Mondragón-Vásquez K; Alcalá-Alcalá S; Lima E; Höpfl H; Herrera-Ruiz D; Morales-Rojas H
Mol Pharm; 2022 Feb; 19(2):414-431. PubMed ID: 34967632
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured Lipid Carriers as a Strategy to Improve the In Vitro Schistosomiasis Activity of Praziquantel.
Kolenyak-Santos F; Garnero C; de Oliveira RN; de Souza AL; Chorilli M; Allegretti SM; Longhi MR; Chaud MV; Gremião MP
J Nanosci Nanotechnol; 2015 Jan; 15(1):761-72. PubMed ID: 26328440
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and bioavailability of different praziquantel brands.
Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
[TBL] [Abstract][Full Text] [Related]
17. Design and in vitro characterization of ivermectin nanocrystals liquid formulation based on a top-down approach.
Starkloff WJ; Bucalá V; Palma SD; Gonzalez Vidal NL
Pharm Dev Technol; 2017 Sep; 22(6):809-817. PubMed ID: 27346432
[TBL] [Abstract][Full Text] [Related]
18. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
[TBL] [Abstract][Full Text] [Related]
19. Dissolution properties of praziquantel-beta-cyclodextrin systems.
el-Arini SK; Leuenberger H
Pharm Dev Technol; 1996 Oct; 1(3):307-15. PubMed ID: 9552314
[TBL] [Abstract][Full Text] [Related]
20. Co-grinding with surfactants as a new approach to enhance in vitro dissolution of praziquantel.
Gaggero A; Jurišić Dukovski B; Radić I; Šagud I; Škorić I; Cinčić D; Jug M
J Pharm Biomed Anal; 2020 Sep; 189():113494. PubMed ID: 32745904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
